GLMD
NASDAQ · Biotechnology
Galmed Pharmaceuticals Ltd
$0.55
-0.02 (-3.14%)
Open$0.57
Previous Close$0.57
Day High$0.57
Day Low$0.55
52W High$2.34
52W Low$0.41
Volume—
Avg Volume214.0K
Market Cap4.41M
P/E Ratio—
EPS$-2.40
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+3,019.3% upside
Current
$0.55
$0.55
Target
$17.25
$17.25
$9.83
$17.25 avg
$23.67
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.71M | 1.77M | 1.41M |
| Net Income | 137.6K | 142.0K | 102.7K |
| Profit Margin | 8.1% | 8.0% | 7.3% |
| EBITDA | 176.3K | 217.6K | 150.4K |
| Free Cash Flow | 176.3K | 155.0K | 130.1K |
| Rev Growth | +12.1% | -7.4% | -2.7% |
| Debt/Equity | 1.54 | 1.34 | 1.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $254.31 | +0.38% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $360.55 | +0.62% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.33 | -1.21% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $499.65 | +1.69% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $631.81 | -0.17% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.52 | +0.74% | 69.3 | 39.97B |